Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2020-09-17 Annual Report
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 92 pages 4.4MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT For the year ended 30 June 2020' and contains detailed sections typical of an annual report, including a Chairman's letter, Directors' report, auditor's independence declaration, corporate governance statement, financial statements, and an independent auditor's report. The content includes comprehensive operational updates, financial highlights, corporate governance, and strategic initiatives, all consistent with a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2020-09-17 English
Appendix 4G and Corporate Governance Statement 28 pages 498.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures. It includes a key to disclosures related to the Corporate Governance Council Principles and Recommendations, and it mentions the corporate governance statement for the financial year ended 30 June 2020. The document is a detailed annexure explaining compliance with corporate governance recommendations, with references to the company's corporate governance statement and website. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a regulatory filing related to corporate governance compliance under ASX rules, serving as a formal disclosure rather than a full annual report or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-09-17 English
Investor Presentation 19 pages 6.6MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and is described as a presentation for the HC Wainwright 22nd Annual Global Investment Conference. It contains detailed information about the company's products, market position, development pipeline, and strategic outlook. The text includes forward-looking statements, company snapshot, product details, and market data, which are typical contents of an investor presentation. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The length is substantial (15,000 characters), and the content is consistent with a presentation aimed at investors rather than a formal report or announcement. Therefore, the document fits the category of an Investor Presentation (IP).
2020-09-15 English
US Sales commence via Online Health Platform 3 pages 127.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Ltd dated September 11, 2020. It announces the commencement of US sales of a new product, GeneType for Breast Cancer Risk Assessment, via an online health platform. The content focuses on product launch details, market availability, pricing, and strategic plans for telehealth delivery. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings or interim report data, and no audit or governance information. The document is a corporate announcement about a commercial development and product launch, which fits best under Capital/Financing Update (CAP) as it relates to business expansion and market activity rather than a financial report or regulatory filing. The document length is 6549 characters, which is substantive and not a mere announcement of a report publication. Therefore, the classification is CAP with high confidence.
2020-09-10 English
Nasdaq Compliance Confirmation 2 pages 119.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited dated September 1, 2020. It discusses the company's compliance with Nasdaq listing requirements, specifically the minimum stockholders' equity rule. The announcement states that the company has raised capital through offerings of American Depositary Shares and has regained compliance with Nasdaq's Equity Rule, closing the listing review. There is no detailed financial report or comprehensive financial data presented; rather, it is an update on the company's capital raising and regulatory compliance status. The document length is 3142 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on Nasdaq compliance and capital raising, which aligns with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-08-31 English
Preliminary Final Report 43 pages 394.7KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E and Preliminary Financial Report for the year ended 30 June 2020' and includes detailed financial results, operational review, management letters, directors' report, and financial statements for the full fiscal year ending June 30, 2020. It contains comprehensive financial data, management discussion, and corporate updates. The document is lengthy (15,000 characters) and is not merely an announcement or certification. The presence of full financial statements and detailed management commentary indicates this is a full annual report. Appendix 4E is an Australian regulatory form for preliminary final reports, which aligns with an annual report filing. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2020-08-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.